Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.46 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609807 | 1.00 | CNR2 (0.58) | CNR2MCHR1VCAM1SMN1; SMN2CA12 | |
| SCHEMBL7611913 | 0.91 | CNR2 (0.67) | CNR2MCHR1VCAM1SMN1; SMN2CA12 | |
| SCHEMBL9307801 | 0.91 | CNR2 (0.67) | CNR2MCHR1VCAM1SMN1; SMN2CA12 | |
| SCHEMBL8101278 | 0.89 | CNR2 (0.64) | CNR2MCHR1VCAM1SMN1; SMN2CA12 | |
| SCHEMBL9351542 | 0.86 | CNR2 (0.48) | CNR2MCHR1SMN1; SMN2CA12CA9 | |
| SCHEMBL6490141 | 0.85 | CNR2 (0.67) | CNR2MCHR1SMN1; SMN2RAB9ASERPINE1 | |
| SCHEMBL3694171 | 0.85 | CNR2 (0.58) | CNR2MCHR1VCAM1SMN1; SMN2CA12 | |
| SCHEMBL7097469 | 0.82 | CNR2 (0.59) | CNR2MCHR1SMN1; SMN2CA12CA9 | |
| SCHEMBL14229013 | 0.82 | CA9 (0.61) | CNR2MCHR1VCAM1SMN1; SMN2CA12 | |
| SCHEMBL7092599 | 0.82 | CNR2 (0.59) | CNR2MCHR1SMN1; SMN2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025920-A1 | Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy | BISCHOFF RAINER (SE) | 2002-02-28 | — | — | US | disclosed |
| US-6291423-B1 | Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy | TRANSGENE S.A. (FR) | 2001-09-18 | — | — | US | disclosed |
| EP-0956050-A1 | NOVEL LIPID COMPLEXES FOR TRANSFERRING AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE, IN PARTICULAR A POLYNUCLEOTIDE INTO A TARGET CELL AND USE IN GENE THERAPY | TRANSGENE S.A. (FR) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998056423-A1 | NOVEL LIPID COMPLEXES FOR TRANSFERRING AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE, IN PARTICULAR A POLYNUCLEOTIDE INTO A TARGET CELL AND USE IN GENE THERAPY | TRANSGENE S.A. (FR) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025920-A1 | Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy | PCYT1A, PLTP, PITPNB | CNR2 3147/4885MCHR1 2906/4885VCAM1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.